产品说明书

CAY10505

Print
Chemical Structure| 1218777-13-9 同义名 : -
CAS号 : 1218777-13-9
货号 : A364016
分子式 : C14H8FNO3S
纯度 : 98%
分子量 : 289.282
MDL号 : MFCD00640727
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 35 mg/mL(120.99 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • p110γ
描述 CAY10505 is a PI3Kγ inhibitor with IC50 value of 30nM. It partially reduced the baicalein-induced Akt phosphorylation at 200nM in neurons[3]. CAY10505 improved hypertension-associated vascular endothelial dysfunction. Oral administration of CAY10505 at dose of 0.6mg/kg daily, for 7 days, significantly improved acetylcholine-induced endothelium dependent relaxation, serum nitrate and (or) nitrite level, glutathione level, and the vascular endothelial lining in DOCA induced hypertensive rats[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.46mL

0.69mL

0.35mL

17.28mL

3.46mL

1.73mL

34.57mL

6.91mL

3.46mL
参考文献

[1]Sun YY, Lin SH, et al. Cell type-specific dependency on the PI3K/Akt signaling pathway for the endogenous Epo and VEGF induction by baicalein in neurons versus astrocytes. PLoS One. 2013 Jul 19;8(7):e69019.

[2]Tyagi S, Sharma S, et al. Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats. Can J Physiol Pharmacol. 2012 Jul;90(7):881-5.

[3]Sun YY, Lin SH, Lin HC, Hung CC, Wang CY, Lin YC, Hung KS, Lien CC, Kuan CY, Lee YH. Cell type-specific dependency on the PI3K/Akt signaling pathway for the endogenous Epo and VEGF induction by baicalein in neurons versus astrocytes. PLoS One. 2013 Jul 19;8(7):e69019. doi: 10.1371/journal.pone.0069019. PMID: 23904909; PMCID: PMC3719842.

[4]Tyagi S, Sharma S, Budhiraja RD. Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats. Can J Physiol Pharmacol. 2012 Jul;90(7):881-5. doi: 10.1139/y2012-089. Epub 2012 Jun 25. PMID: 22731503.